The authors examined cellular mechanisms involved in anti-tumor reactivity
induced by the murine MT-9GI mammary tumor line, which was transduced to se
crete granulocyte macrophage-colony-stimulating factor (GM-CSF). Compared w
ith the parental MT-901 tumor, MT-9G1 subcutaneous tumors elicited an influ
x of CD4(+) cells and dendritic cells. Secondary in vitro activation of tum
or-draining lymph node cells with anti-CDS and interleukin-2 resulted in ef
fector cells that can mediate regression of established pulmonary metastase
s after adoptive transfer. In vivo depletion of T-cell subsets showed that
tumor regression required CD4(+) tumor-draining lymph node cells rather tha
n CD8(+) cells. The activated CD4(+) cells expressed CD95L and mediated lys
is of CD95(+) MT-901 tumor cells, which were major histocompatibility compl
ex class II negative. The CD4(+) cells also released GM-CSF in response to
tumor stimulation. A Fas fusion protein inhibited tumor lysis and GM-CSF re
lease by the CD4(+) cells. These studies document an alternate pathway by w
hich CD4(+) immune cells may recognize major histocompatibility complex cla
ss II-deficient tumors in which CD95L-bearing T cells induced an anti-tumor
response mediated via CD95L:CD95.